Cipla submits application with USFDA for generic version of asthma drug

The company has submitted an abbreviated new drug application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the US Food and Drug Administration (USFDA), Cipla said in a regulatory filing.

from Moneycontrol Business News https://ift.tt/2TgOd2J